Stockreport

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC [Yahoo! Finance]

CG Oncology, Inc. - Common stock  (CGON) 
PDF - First randomized registrational trial to evaluate an investigational therapy in intermediate-risk NMIBC IRVINE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CG Oncolog [Read more]